Irogue Igbinosa, MD is a Maternal-Fetal Medicine fellow at Stanford University. She graduated from the University of Houston and earned her medical degree at Baylor College of Medicine. She subsequently completed her residency in Obstetrics and Gynecology Residency at Louisiana State University School of Medicine Baton Rouge. After residency, she was an AAMC-CDC Public Health Policy Fellow able to serve in the CDC Emergency Operations Center and contribute to research for health care providers regarding the management of the Zika virus in pregnant persons. Dr. Igbinosa's current research interests include severe maternal morbidity and mortality, health disparities and equity, anemia in pregnancy, infectious diseases, and clinical trials.
- Editorial: How COVID-19 has affected maternal-fetal medicine and obstetrics? Current opinion in obstetrics & gynecology 2021; 33 (5): 416-418
Inflammatory bowel disease and the impact on rates of chorioamnionitis, sepsis, and severe maternal morbidity
MOSBY-ELSEVIER. 2021: S441–S442
View details for Web of Science ID 000621547401249
- Use of Remdesivir for Pregnant Patients with Severe Novel 2019 Coronavirus Disease. American journal of obstetrics and gynecology 2020
The obstetric research landscape: a cross-sectional analysis of clinical trials from 2007-2020.
American journal of obstetrics & gynecology MFM
Obstetric complications impact over a third of women globally, but are underrepresented in clinical research. Little is known about the comprehensive obstetric clinical trial landscape, how it compares to other fields, or factors associated with the successful completion of obstetric trials.To characterize obstetric clinical trials registered on ClinicalTrials.gov with the primary objective of identifying features associated with early discontinuation and results reporting.This is a cross-sectional study with descriptive, logistic regression and cox regression analyses of clinical trials registered on ClinicalTrials.gov. Our primary exposure variables were trial focus (obstetric or non-obstetric) and trial funding (industry, United States government or academic). We conducted additional exploratory analyses of other trial features including design, enrollment, and therapeutic focus. We examined the associations of exposure variables and other trial features with two primary outcomes: early discontinuation and results reporting.We downloaded data for all studies (n=332,417) registered on ClinicalTrials.gov from October 1, 2007 to March 9, 2020 from the Aggregate Analysis of the ClinicalTrials.gov database. We excluded studies with a non-interventional design (n=63,697) and those registered before October 1, 2007 (n=45,209). 4,276 (1.9%) obstetric trials (i.e. interventional studies), and 219,235 (98.1%) non-obstetric trials were compared. Among all trials, 2.8% of academic-funded trials, 1.9% of United States government-funded trials, and 0.4% of industry-funded trials focused on obstetrics. The quantity of obstetric trials increased over time (10.8% annual growth rate). Compared to non-obstetric trials, obstetric trials had a greater risk of early discontinuation (adjusted hazard ratio 1.40, 95% confidence interval: 1.21 to 1.62, p<0.0001) and similar odds of results reporting (adjusted odds ratio 0.89, 95% confidence interval: 0.72 to 1.10, p=0.19). Among obstetric trials funders after controlling for confounding variables, United States government-funded trials were at lowest risk of early discontinuation (US government adjusted hazard ratio 0.23, 95% confidence interval 0.07 to 0.69, p=0.009, industry reference; academic adjusted hazard ratio 1.04, 95% confidence interval 0.62 to 1.74, p=0.88). Academic-funded trials had the lowest odds of results reporting after controlling for confounding variables (academic institutions adjusted odds ratio 0.39, 95% confidence interval 0.22 to 0.68, p=0.0009; industry reference; US government adjusted odds ratio 1.06 95% confidence interval 0.53 to 2.09, p=0.87).Obstetric trials represent only 1.9% of all clinical trials in ClinicalTrials.gov and have comparatively poor completion. All stakeholders should commit to increasing the number of obstetric trials and improving their completion and dissemination to ensure clinical research reflects the obstetric burden of disease and advances maternal health.
View details for DOI 10.1016/j.ajogmf.2020.100253
View details for PubMedID 33043288
View details for PubMedCentralID PMC7537600
- Relationships of uterine fibroids to racial/ethnic disparities in severe maternal morbidity MOSBY-ELSEVIER. 2020: S170–S171
- Early discontinuation and results reporting in obstetric clinical trials: An analysis of 3317 clinicaltrials.gov investigations MOSBY-ELSEVIER. 2020: S55–S56
- The obstetric clinical trial landscape: a characterization of clinicaltrials.gov investigations from 2007-2018 MOSBY-ELSEVIER. 2020: S459–S460
- Antepartum anemia and racial/ethnic disparities in blood transfusion in california MOSBY-ELSEVIER. 2020: S304